The effect of probiotics on allergic rhinitis and asthma

The effects of probiotic on clinical findings in patients with allergic rhinitis and asthma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161215031429N3

Enrollment

Registered

2018-10-02

Start date

2018-10-07

Completion date

Unknown

Last updated

2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Asthma. Condition 2: Allergic Rhinitis. Predominantly allergic asthma Vasomotor and allergic rhinitis

Interventions

Intervention 1: Intervention group: Familact probiotic capsules produced by Zist Takhmir Co. (Tehran, Iran) will be administered to patients with asthma and allergic rhinitis for 8 weeks, along with r

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: All people over the age of 15, including the girl and the boy, who have allergic rhinitis. All people over the age of 15, including boys and girls, who have asthma.

Exclusion criteria

Exclusion criteria: Using antibiotics in the past 4 weeks Food allergy Lactose intolerance suffering from chronic diseases Use of corticostroids Suffering from underlying diseases other than asthma Suffering from other kinds of rhinitis and respiratory diseases

Design outcomes

Primary

Measure	Time frame
Cough. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Standard Questionnaire.;Post Nasal Drip. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Physical Examination.;Nasal Discharge. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Physical Examination.;Nasal polyps. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Physical Examination.;Night snoring. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Standard questionnaire.;Sleep disturbances. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Standard questionnaire.;Turbinates hypertrophy. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Physical Examination.;Quality of life. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: SF-36 quality of life questionnaire.	—

Measure

Time frame

Cough. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Standard Questionnaire.;Post Nasal Drip. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Physical Examination.;Nasal Discharge. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Physical Examination.;Nasal polyps. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Physical Examination.;Night snoring. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Standard questionnaire.;Sleep disturbances. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Standard questionnaire.;Turbinates hypertrophy. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: Physical Examination.;Quality of life. Timepoint: Before intervention and 4 and 8 weeks after intervention. Method of measurement: SF-36 quality of life questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Rezapor

Tabriz University of Medical Sciences

prezapour78@yahoo.com+98 41 3333 9589

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026